Fig. 5: BMPR1A, ΔNp73, and NANOG expression at diagnosis are correlated with patient outcome.

Percentage of AML patients in remission or relapse 3 years after diagnosis, according to BMPR1A, ΔNp73 or NANOG expression levels separately (n = 19) (a) or in combination (n = 13) (b). c Overall survival (OS) curve of AML patients from the date of sampling onwards, by using the Kaplan−Meier method. The level of significance was determined by the log-rank test (n = 52; 23 high and 29 low NANOG level). d Overall survival (OS) curve of AML patients from the date of sampling onwards, by using the Kaplan−Meier method. TCGA dataset from AML patients of the intermediate group. e Schematic representation of the role played by BMPs on homeostasis under healthy conditions (top) and the cascade of dysregulations associated with increased concentration of BMP4 in the microenvironment of leukemic immature cells (bottom)